Citadel Advisors
INSP icon

Citadel Advisors’s Inspire Medical Systems INSP Stock Holding History

Citadel Advisors’s Portfolio INSP Stock Details INSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Sell
51,300
-9,500
-16% -$451K ﹤0.01% 6263
2026
Q1 		$3.14M Buy
60,800
+25,500
+72% +$1.79M ﹤0.01% 5179
2025
Q4 		$3.26M Sell
35,300
-43,300
-55% -$4.14M ﹤0.01% 5017
2025
Q3 		$5.83M Buy
78,600
+51,900
+194% +$5.25M ﹤0.01% 4080
2025
Q2 		$3.46M Sell
26,700
-66,600
-71% -$9.66M ﹤0.01% 4723
2025
Q1 		$14.9M Buy
93,300
+27,800
+42% +$5.03M ﹤0.01% 2369
2024
Q4 		$12.1M Buy
65,500
+5,600
+9% +$1.09M ﹤0.01% 2731
2024
Q3 		$12.6M Sell
59,900
-31,400
-34% -$5.45M ﹤0.01% 2579
2024
Q2 		$12.2M Sell
91,300
-27,800
-23% -$5.26M ﹤0.01% 2524
2024
Q1 		$25.6M Buy
119,100
+36,500
+44% +$7.15M ﹤0.01% 1829
2023
Q4 		$16.8M Buy
82,600
+23,900
+41% +$3.87M ﹤0.01% 2201
2023
Q3 		$11.6M Buy
58,700
+6,700
+13% +$1.69M ﹤0.01% 2491
2023
Q2 		$16.9M Buy
52,000
+3,900
+8% +$1.11M ﹤0.01% 2058
2023
Q1 		$11.3M Buy
48,100
+1,300
+3% +$329K ﹤0.01% 2648
2022
Q4 		$11.8M Buy
46,800
+14,300
+44% +$3.05M ﹤0.01% 2601
2022
Q3 		$5.76M Sell
32,500
-10,300
-24% -$2.07M ﹤0.01% 3636
2022
Q2 		$7.82M Buy
42,800
+21,300
+99% +$4.25M ﹤0.01% 3008
2022
Q1 		$5.52M Buy
21,500
+6,000
+39% +$1.37M ﹤0.01% 3987
2021
Q4 		$3.57M Buy
15,500
+4,000
+35% +$977K ﹤0.01% 4982
2021
Q3 		$2.68M Sell
11,500
-9,100
-44% -$1.9M ﹤0.01% 5634
2021
Q2 		$3.98M Sell
20,600
-49,900
-71% -$9.9M ﹤0.01% 4947
2021
Q1 		$14.6M Buy
70,500
+1,900
+3% +$404K ﹤0.01% 2407
2020
Q4 		$12.9M Buy
68,600
+39,400
+135% +$6.44M ﹤0.01% 2319
2020
Q3 		$3.77M Buy
29,200
+7,700
+36% +$848K ﹤0.01% 3582
2020
Q2 		$1.87M Buy
21,500
+16,000
+291% +$1.23M ﹤0.01% 4702
2020
Q1 		$332K Sell
5,500
-5,000
-48% -$370K ﹤0.01% 7148
2019
Q4 		$779K Sell
10,500
-8,100
-44% -$521K ﹤0.01% 6050
2019
Q3 		$1.14M Buy
18,600
+14,000
+304% +$922K ﹤0.01% 5376
2019
Q2 		$279K Sell
4,600
-4,900
-52% -$264K ﹤0.01% 7692
2019
Q1 		$539K Buy
+9,500
New +$513K ﹤0.01% 6665

Other funds holding INSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's INSP Position: Q2 2026 in Review

Citadel Advisors increased its Inspire Medical Systems (INSP) stake by 28% in Q2 2026, buying an estimated $5.32M and bringing the position to 506,334 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Citadel Advisors first reported a position in INSP in Q2 2018 and has held it in 33 quarters since. The position peaked at $159M in Q4 2022. 275 funds tracked by Wall St. Rank hold INSP as of Q2 2026.

  • Citadel Advisors held 506,334 shares of Inspire Medical Systems worth $22.6M as of Q2 2026.
  • Citadel Advisors bought 112,258 Inspire Medical Systems shares in Q2 2026, an estimated $5.32M.
  • Inspire Medical Systems made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2410 holding.
  • Citadel Advisors first reported a position in Inspire Medical Systems in Q2 2018 and has held it in 33 quarters since.
  • Citadel Advisors's Inspire Medical Systems position peaked at $159M in Q4 2022.
  • 275 funds tracked by Wall St. Rank held Inspire Medical Systems as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.